HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 from hepatitis C virus
SIGMA/SRP2151 - recombinant, expressed in E. coli, ≥80% (SDS-PAGE)
Synonym: Hepatitis C virus NS3 protease; NS3; NS4ANS3 complex; pfam02907
Product Type: Chemical
Immunoblotting HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 Cat. No. SRP2151: HCV-NS4A/NS3-1b Protease, Histag, strain HC-J4 was separated on SDS-PAGE using 1-3 μg protein (left); and a protein marker (right).
| assay | ≥80% (SDS-PAGE) |
| biological source | hepatitis C virus |
| color | colorless to clear |
| concentration | 500 μg/mL |
| form | frozen liquid |
| mol wt | ~22.7 kDa |
| NCBI accession no. | X61596   |
| packaging | pkg of 10 μg |
| recombinant | expressed in E. coli |
| shipped in | dry ice |
| storage temp. | −70°C |
| Biochem/physiol Actions: | Persistent infection with hepatitis C virus (HCV) is a common cause of chronic liver disease, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. HCV is an enveloped, single-stranded RNA virus with a 9.6-kb positive-polarity genome, which encodes a polyprotein precursor of about 3,000 amino acids. The HCV polyprotein is proteolytically processed by cellular and HCV proteases into at least 10 distinct products. NS3 serine protease and helicase as well as NS5B RNA-dependent RNA polymerase are believed to be components of a replication complex responsible for viral RNA replication and have been shown to be essential for the HCV replication in chimpanzees. These HCV enzymes have been the major targets for the development of HCV-specific therapeutics during the past decade. The HCV NS3/4A protease is responsible for cleavage at four sites within the HCV polyprotein to generate the N termini of the NS4A, NS4B, NS5A, and NS5B proteins. It has been shown that the central region (amino acids 21-30) of the 54-residue NS4A protein is essential and sufficient for the enhancement of proteolytic activity of the NS3 serine protease. In recent phase I trials, a 2-3-log reduction of HCV viral load was observed after a 2-day treatment with a serine protease inhibitor, which provided the first proof-of-concept evidence that HCV NS3/4A protease inhibitors could be a new therapeutic option for hepatitis C patients. |
| Physical form: | Clear and colorless frozen liquid solution |
| Preparation Note: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. While working, please keep sample on ice. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥80% (SDS-PAGE) |
| Storage Temp. | −70°C |
| UNSPSC | 12352200 |